Efinaconazole Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 7 pharmaceutical companies such as BAUSCH, PADAGIS US, TEVA PHARMS USA and others. It is marketed under 2 brand names, including JUBLIA, EFINACONAZOLE. Available in 1 different strength, such as 10%, and administered through 1 route including SOLUTION;TOPICAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 7 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"80481","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"e50f2d6bbcc44ef9bbcb","publication_number":"US7214506B2","cleaned_patent_number":"7214506","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-02-22","publication_date":"2007-05-08","legal_status":"Granted"} US7214506B2 08 May, 2007 Granted 22 Feb, 2026
{"application_id":"80516","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"553322a1b9e94b5793cd","publication_number":"US9877955B2","cleaned_patent_number":"9877955","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-01-03","publication_date":"2018-01-30","legal_status":"Granted"} US9877955B2 30 Jan, 2018 Granted 03 Jan, 2028
{"application_id":"80517","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"553322a1b9e94b5793cd","publication_number":"US10512640B2","cleaned_patent_number":"10512640","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-01-03","publication_date":"2019-12-24","legal_status":"Granted"} US10512640B2 24 Dec, 2019 Granted 03 Jan, 2028
{"application_id":"80571","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"f8f31878a6d94e329482","publication_number":"US10828369B2","cleaned_patent_number":"10828369","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-01-03","publication_date":"2020-11-10","legal_status":"Granted"} US10828369B2 Formulation 10 Nov, 2020 Granted 03 Jan, 2028
{"application_id":"80518","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"553322a1b9e94b5793cd","publication_number":"US11213519B2","cleaned_patent_number":"11213519","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-01-03","publication_date":"2022-01-04","legal_status":"Granted"} US11213519B2 04 Jan, 2022 Granted 03 Jan, 2028
{"application_id":"122905","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"","publication_number":"US11872218B2","cleaned_patent_number":"11872218","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-01-03","publication_date":"2024-01-16","legal_status":"Granted"} US11872218B2 16 Jan, 2024 Granted 03 Jan, 2028
{"application_id":"80498","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"553322a1b9e94b5793cd","publication_number":"US9566272B2","cleaned_patent_number":"9566272","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-01-03","publication_date":"2017-02-14","legal_status":"Granted"} US9566272B2 14 Feb, 2017 Granted 03 Jan, 2028
{"application_id":"80570","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"f8f31878a6d94e329482","publication_number":"US10105444B2","cleaned_patent_number":"10105444","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-07-08","publication_date":"2018-10-23","legal_status":"Granted"} US10105444B2 Formulation 23 Oct, 2018 Granted 08 Jul, 2030
{"application_id":"80569","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"f8f31878a6d94e329482","publication_number":"US9861698B2","cleaned_patent_number":"9861698","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-07-08","publication_date":"2018-01-09","legal_status":"Granted"} US9861698B2 Formulation 09 Jan, 2018 Granted 08 Jul, 2030
{"application_id":"80566","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"f8f31878a6d94e329482","publication_number":"US8039494B1","cleaned_patent_number":"8039494","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-07-08","publication_date":"2011-10-18","legal_status":"Granted"} US8039494B2 18 Oct, 2011 Granted 08 Jul, 2030
{"application_id":"80567","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"f8f31878a6d94e329482","publication_number":"US8486978B2","cleaned_patent_number":"8486978","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-10-24","publication_date":"2013-07-16","legal_status":"Granted"} US8486978B2 Formulation 16 Jul, 2013 Granted 24 Oct, 2030
{"application_id":"80568","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"f8f31878a6d94e329482","publication_number":"US9302009B2","cleaned_patent_number":"9302009","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-10-24","publication_date":"2016-04-05","legal_status":"Granted"} US9302009B2 Formulation 05 Apr, 2016 Granted 24 Oct, 2030
{"application_id":"80537","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"64e2c136edad4571b22d","publication_number":"US10864274B2","cleaned_patent_number":"10864274","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-10-02","publication_date":"2020-12-15","legal_status":"Granted"} US10864274B2 15 Dec, 2020 Granted 02 Oct, 2034
{"application_id":"80563","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"1a835a524888499092ce","publication_number":"US11654139B2","cleaned_patent_number":"11654139","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-10-02","publication_date":"2023-05-23","legal_status":"Granted"} US11654139B2 23 May, 2023 Granted 02 Oct, 2034
{"application_id":"80521","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"64e2c136edad4571b22d","publication_number":"US10342875B2","cleaned_patent_number":"10342875","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-10-02","publication_date":"2019-07-09","legal_status":"Granted"} US10342875B2 Formulation 09 Jul, 2019 Granted 02 Oct, 2034
{"application_id":"80553","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"d8ed89db36a3489c8113","publication_number":"US10828293B2","cleaned_patent_number":"10828293","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-10-02","publication_date":"2020-11-10","legal_status":"Granted"} US10828293B2 10 Nov, 2020 Granted 02 Oct, 2034
{"application_id":"80536","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"64e2c136edad4571b22d","publication_number":"US9662394B2","cleaned_patent_number":"9662394","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-10-02","publication_date":"2017-05-30","legal_status":"Granted"} US9662394B2 Formulation 30 May, 2017 Granted 02 Oct, 2034
{"application_id":"80542","ingredient":"EFINACONAZOLE","trade_name":"JUBLIA","family_id":"7ae854cfd7354e25a544","publication_number":"US10478601B2","cleaned_patent_number":"10478601","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-04-25","publication_date":"2019-11-19","legal_status":"Granted"} US10478601B2 Formulation 19 Nov, 2019 Granted 25 Apr, 2035

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Efinaconazole

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.